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Abstract: The present study analyzed the transepithelial transport of the dietary anti-inflammatory
peptide, γ-glutamyl valine (γ-EV). γ-EV is naturally found in dry edible beans. Our previous
study demonstrated the anti-inflammatory potency of γ-EV against vascular inflammation at a
concentration of 1mM, and that it can transport with the apparent permeability coefficient (Papp ) of
1.56 × 10−6 ± 0.7 × 10−6 cm/s across the intestinal Caco-2 cells. The purpose of the current study was
to explore whether the permeability of the peptide could be enhanced and to elucidate the mechanism
of transport of γ-EV across Caco-2 cells. The initial results indicated that γ-EV was nontoxic to the
Caco-2 cells up to 5 mM concentration and could be transported across the intestinal cells intact.
During apical-to-basolateral transport, a higher peptide dose (5 mM) significantly (p < 0.01) enhanced
the transport rate to 2.5 × 10−6 ± 0.6 × 10−6 cm/s. Cytochalasin-D disintegrated the tight-junction
proteins of the Caco-2 monolayer and increased the Papp of γ-EV to 4.36 × 10−6 ± 0.16 × 10−6 cm/s
(p < 0.001), while theaflavin 30 -gallate and Gly-Sar significantly decreased the Papp (p < 0.05), with
wortmannin having no effects on the peptide transport, indicating that the transport route of γ-EV
could be via both PepT1-mediated and paracellular.
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1. Introduction
Dietary bioactive peptides have been shown to exhibit numerous health-modulating,
beneficial biological activities, such as anti-inflammatory, antioxidant, antihypertensive,
immunomodulatory, anticancer, and antithrombotic activities [1]. However, to exert such
health-beneficial activities, these food-derived bioactive peptides must overcome two
critical physiological barriers in order to be absorbed in the blood circulation intact. The
first barrier is to survive the extensive hydrolysis in the gastrointestinal tract (GIT), and the
second is to overcome the permeability across the intestinal epithelium [2]. A monolayer
of human intestinal carcinoma-derived cell line, Caco-2, is generally used for transport
and permeability studies of various drugs and peptides across the intestinal epithelium, as
it mimics the human GIT in terms of the microvilli structure, tight junctions, and overall
biological functions [3,4].
Bioactive peptides may range from 2 to 20 amino acid residues, and their transepithelial transport route depends upon their overall charge, molecular mass, hydrophobicity,
and tendency to aggregate [5]. Numerous studies on the transport of food-derived bioactive peptides have been reported, and they may all have different transport mechanisms.
The three main routes of peptide transport across the intestinal cells include: (i) the
passive paracellular transport (via the tight junctions of the intestinal cells); (ii) transportermediated active transport, via the PepT1 transporter, particularly for di- and tripeptides;
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and (iii) transcytosis, which involves the endocytotic uptake of the peptide, vesicular transport within the cell, and basolateral secretion [6]. These routes of transepithelial transport
were investigated using selective inhibitors or modulators for each of these specific routes.
For instance, for the investigation of the paracellular pathway, transport was carried out in
the presence of compounds such as cytochalasin D, which disrupted the tight junctions
by modifying the cytoskeletal structure [7]. On the other hand, theaflavins enhanced the
intestinal barrier by expressing more tight-junction proteins. Similarly, the compound
glycyl-sarcosine (Gly-Sar) is a competitive inhibitor of the PepT1 transporter due to its
higher affinity (lower Km or Michaelis constant) for the transporter [8]. Finally, wortmannin
is a specific noncompetitive and irreversible inhibitor of the phosphatidylinositol-3-kinase,
and thus an inhibitor of transcytosis [9].
γ-glutamyl valine (γ-EV) is a naturally occurring bioactive dipeptide that is primarily found in foods such as legumes (i.e., common beans, soybeans, black gram), garlic,
onions, cheese, and other fermented foods [10]. γ-EV has been characterized as an antiinflammatory peptide, as it had previously been demonstrated to exhibit in vitro antiinflammatory activities against vascular [11], gastrointestinal [12], and adipocyte [13]
inflammation. The peptide had also shown in vivo anti-inflammatory effects in dextran
sodium sulfate-induced mouse [12] and porcine models of colitis [14] and in
lipopolysaccharide-induced mouse model of sepsis [15]. Despite these in vivo antiinflammatory studies being present, none of them clearly acknowledged the mechanism of
absorption of γ-EV across the intestinal layer. Our previous study evaluated the in vitro
transport efficiency of the γ-EV peptide across the intestinal Caco-2 monolayer, and reported the apparent permeability (Papp ) of γ-EV to be 1.56 × 10−6 cm/s [11]. The Papp value
of γ-EV was found comparable to other dietary bioactive peptides, which were evaluated
in both in vitro and in vivo studies [5,16–18]. Thus, the present study investigates how the
current Papp of γ-EV could be improved and elucidates the mechanisms of transport of
γ-EV across the Caco-2 monolayer as a useful model to explore the peptide transport.
2. Materials and Methods
2.1. Chemicals
The γ-EV peptide was synthesized chemically (purity >98%) through GenScript Inc.,
Piscataway, NJ, USA. All the chemicals used for the transport mechanism study were
obtained from Millipore Sigma, Burlington, MA, USA: theaflavin 30 -gallate (#PHL83343),
wortmannin (#W1628), cytochalasin D (#C8273), Gly-Sar (#G3127), 40 ,6-Diamidino-2phenylindole (DAPI) (#D9542), paraformaldehyde (#158127), Triton X-100 (#T8787), bovine
serum albumin (BSA) (A2153), 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid
(HEPES) (H4034), and 4-Morpholineethanesulfonic acid (MES) (M3671). The primary
antibodies used in immunofluorescence (IF) and Western immunoblotting (WB) were as
follows: anti-zonula occludens-1 (ZO-1, 1:20 (IF) and 1:200 (WB) dilutions) (Invitrogen,
#61-7300), anti-claudin-1 (Invitrogen, #37-4900, 1:50 (IF) and 1:100 (WB) dilutions), antioccludin (Invitrogen, #33-1500, 1:50 (IF) and 1:200 (WB) dilutions), and anti-β-actin (Sigma,
#A5316, 1:5000 dilution). The secondary antibodies used for the Western immunoblotting
experiments were IRDye 800RD goat anti-rabbit antibody (Li-Cor, #926-32211, 1:10,000
dilution) and IRDye 680RD goat anti-mouse antibody (Li-Cor, #926-68070, 1:10,000 dilution). The secondary antibodies used for the immunofluorescence experiments were
goat anti-rabbit (Alexa Fluor 488) (Abcam, #ab150077, 1:500 dilution) and goat anti-mouse
(Alexa Fluor 594) (Abcam, #ab150116, 1:500 dilution).
2.2. Caco-2 Cell Culture
Caco-2 (ATCC® HTB-37™) cells, at a passage number between 24–26, were used for
the experiments. Eagle’s Minimum Essential Medium (EMEM) (ATCC® 30-200) with 20%
fetal bovine serum (FBS) (Gibco, #10-437-028) and 1% penicillin-streptomycin (Pen-Strep)
(10,000 U/mL) (Gibco, #15140122) was used for the proliferation of Caco-2 cells. The cells
were kept in a humidified environment at 37 ◦ C and 5% CO2 . Caco-2 cells were proliferated
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until they were 80% confluent, with media being replaced with fresh media every other
day, followed by sub-culturing onto 12 mm Transwell inserts with 0.4 µm pore polyester
membrane (Corning, #3460) (50,000 cells/insert) for the transport experiments.
2.3. Cell Viability Assay
A clear-bottom 96-well black plate (VWR, #29444-008) was seeded with Caco-2 cells
(40,000 cells/well) and grown for 15 days in EMEM media (20% FBS and 1% Pen-Strep)
to achieve differentiation of the cells. The MTT assay kit (Abcam, #ab211091) was used to
test the cell-viability assay following the manufacturer’s guidelines, as described in the
earlier study [11]. For the time-course study, a concentration of 1 mM γ-EV was used for
determining the cell toxicity, by incubating it on the Caco-2 cells for 2, 4, and 6 h. For the
dose study, the cell toxicity of γ-EV was tested for different doses, such as 2.5, 3, 4, 5, and
10 mM, after incubating the peptide on the cells for 2 h. After the treatment period, the
cell media was discarded and replaced with a mixture of 50 µL of the MTT reagent and
50 µL of serum-free EMEM media. After the incubation period of 3 h at 37 ◦ C, the MTTsupplemented media was replaced with 150 µL of MTT solvent. Following that, the plates
were incubated on an orbital shaker (200 rpm, 37 ◦ C) (MaxQ 4450, Thermo Fischer Scientific,
Waltham, MA, USA) for 15 min, in dark, after which the absorbance of the plate was read
at 590 nm (Synergy H1 microplate reader, BioTek, Winooski, VT, USA). The background
control readings were subtracted from each of the wells and the cell-viability percentage
(%) was calculated using the formula cell viability % = (sample/control) × 100, where the
control was cells with no γ-EV treatment, and the sample was the γ-EV treated cells.
2.4. Transport Assay
In order to determine whether the current Papp of γ-EV could be improved, two sets of
transport experiments were performed: first, with varying the time of γ-EV incubation; and
second, with varying the dose of γ-EV. The transport studies were performed as described
in an earlier study [11]. Briefly, for both experiments, Caco-2 cells were grown onto the
12-well Transwell inserts (50,000 cells/insert) for 21 days, and the media was changed
every other day. The apical side contained 0.5 mL of media, while the basal side of the
inserts contained 1.5 mL of media. The transepithelial electrical resistance (TEER) values of
the inserts were measured on the alternate days continuously for 21 days using EVOM2
paired with STX2 chopstick electrodes (World Precision Instruments, Sarasota, FL, USA).
Caco-2 cells containing wells with EMEM growth medium with a TEER value greater than
or equal to 400 Ωcm2 were selected for the transport experiments. The TEER values greater
than 260 ± 65 Ωcm2 are generally recommended for the transport study [4]. On the 21st
day, the EMEM media was removed and the warm Hank’s Balanced Salt Solution (HBSS)
(Gibco, #14025076) was used to wash the cells. The apical layer was then replaced with
HBSS at a pH of 6.5 (pH adjusted with 10 mM MES), while the basal layer was replaced
with HBSS at a pH of 7.4 (pH adjusted with 25 mM HEPES). The cells were kept for 15 min
at 37 ◦ C and 5% CO2 , after which the TEER values were measured again before the start of
the experiment.
For the time-course study, 1 mM γ-EV dissolved in 0.5 mL of HBSS (pH 6.5) was
replaced in the apical layer of the inserts with the basolateral layer still containing 1.5 mL
HBSS at pH 7.4. The plate was incubated at 37 ◦ C (MaxQ 4450, Thermo Fischer Scientific,
Bedford, MA, USA) on an orbital shaker (200 rpm) for 2, 4, and 6 h. At the end of
each time point, the apical and basal layer solutions were collected, and the amount of
γ-EV transported was analyzed via liquid chromatography coupled with tandem mass
spectrometry (LC-MS/MS). A similar approach was used for the variable dose study, where
instead of using 1 mM, two higher doses of γ-EV (2.5 mM and 5 mM) were dissolved
in 0.5 mL HBSS (pH 6.5) and replaced in the apical layer of the inserts. In this case, the
plate was incubated at 37 ◦ C for 2 h on an orbital shaker, after which the apical and basal
layer solutions were collected and analyzed by LC-MS/MS. The Papp of the peptide was
calculated by the following formula: Papp = (dQ/dt) (1/AC0 ), where dQ/dt is the transport
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rate (µmol/Ls), A is the surface area of the inserts, and C0 is the initial concentration of the
peptide concentration on the apical side (µmol/L).
In all the cases, after collecting the solutions, the Caco-2 cells were also harvested from
the inserts using 80 µL of RIPA lysis and extraction buffer (Thermo Scientific, #89900) for
the analysis of the tight-junction proteins through Western immunoblotting.
2.5. Transport-Mechanism Assay
The route of transport of γ-EV across Caco-2 monolayer cells was determined using
1 mM γ-EV transported for 2 h, following the same protocol as mentioned in Section 2.4.
However, in this case, four transport inhibitors were used prior to γ-EV addition in the
apical layer, to elucidate the mechanism of transport. Theaflavin 30 -gallate (TF30 G) (20 µM),
a cell tight-junction enhancer, was added to the EMEM growth medium 24 h before the
experiment. Wortmannin (a transcytosis inhibitor, 1 µM), cytochalasin D (a cell tightjunction disruptor, 0.5 µg/mL), and Gly-Sar (PepT1 transporter inhibitor, 25 mM) were
added 30 min before γ-EV addition in the HBSS buffer (pH 6.5). After the treatment
was over, the apical and basal layers were collected, and the concentration of γ-EV was
analyzed and represented via Papp . For this study, some of the replicate inserts were
used for harvesting the Caco-2 cells for analyzing the tight-junction proteins via Western
immunoblotting, while some of the inserts were used for visualizing the tight-junction
proteins through immunofluorescence.
2.6. Western Immunoblotting
The Caco-2 cell lysates were mixed with 2×Laemmli buffer to load 30 µg protein
into each well of a 4−20% gradient gel (Biorad, #4561096), and Western immunoblotting
was performed as described earlier [11]. The proteins were separated by sodium dodecyl
sulfate−polyacrylamide gel electrophoresis (SDS-PAGE), after which they were transferred
onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). After the transfer, the
membranes were blocked for 1.5 h using the Odyssey blocking buffer in TBS (Li-Cor,
#927-50000), after which they were incubated overnight at 4 ◦ C with the desired antibodies
and diluted in Odyssey blocking buffer at their recommended dilutions (as mentioned
in Section 2.1). The next day, the membranes were washed (x3) with Tris-Buffered Saline,
0.1% Tween 20 (TBST) and incubated with the secondary antibodies (IRDye 680RD goat
anti-mouse IgG and/or IRDye 800CW goat antirabbit IgG) at room temperature for 1 h in
dark. The membranes were again washed (x2) with TBTS, and the proteins bands were
detected via red and green fluorescent channels through the Odyssey CLx imaging system
(Li-Cor Biosciences). Densitometrical quantification was done for the protein expression
using the Image Studio software from Li-Cor, and β-actin expression was used as a loading
control to normalize each blot.
2.7. Immunofluorescence
Once apical layer solutions were collected, the Caco-2 monolayer cells on the inserts
were washed immediately with warm phosphate buffered saline (PBS), and cells were not
allowed to dry from this point on. For fixation, 250 µL of 4% paraformaldehyde (PFA)
(dissolved in warm PBS) was added onto the cells for 20 min at room temperature. The
PFA was then discarded, and the cells were washed gently with PBS, 3 times for 5 min each,
on a rocker. Following that, 250 µL of permeabilizing buffer (0.1% Triton X-100 in PBS)
was added to each insert for 5 min at room temperature. After incubation, the buffer was
removed and the cells were again washed with PBS, 3 times for 5 min each. Next, 250 µL
of blocking buffer (1% BSA in PBS) was added to each well and kept for 60 min at room
temperature on a rocker. After blocking, the buffer was removed and washed 3 times with
PBS, and then 250 µL of the desired primary antibody solution (in 0.1% BSA in PBS) was
added to each well. The plate was sealed and stored at 4 ◦ C overnight. The next day, the
primary antibody solution was removed, and the cells were washed 3 times with PBS, after
which 250 µL of the respective secondary antibody solution (1:500 dissolved in 1% BSA in
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PBS) was added to the inserts for 60 min at room temperature and in dark conditions. After
60 min, the secondary antibody was removed and the cells were washed with PBS 3 times,
and then 250 µL of the nuclear stain DAPI (1:10,000 in 0.1% BSA in PBS) was added to the
inserts for exactly 10 min. After DAPI incubation was over, the cells were washed with PBS
3 times and the plate was covered to protect it from light, and the images were captured
via EVOS Cell Imaging Systems (Thermo Fischer Scientific, Bedford, MA, USA).
2.8. Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS)
LC-MS/MS was used to detect the γ-EV content after the transport study. The instrument used was the Shimadzu LC system (Nexera X2, Columbia, MD, USA), interfaced
with a Sciex QTRAP 6500+ mass spectrometer (Redwood City, CA, USA), equipped with a
TurboIonSpray (TIS) electrospray ion source (ESI). The LC separation was achieved with
an Agilent Eclipse XDB-C18 (3.5 µm, 100 × 3.0 mm, Santa Clara, CA, USA) at a flow rate
of 0.5 mL/min. The mobile phases and gradient used were as previously described [11].
Analyst software (version 1.6.3, Redwood City, CA, USA) was used for the sample acquisition control and data analysis. The manufacturer’s recommendations were used for
tuning and calibration of the SCIEX QTRAP 6500+ mass spectrometer. The parameters for
the ESI operation were as follows: 5500 V ion spray voltage; 500 ◦ C source temperature;
ion source gas 1, gas 2, and curtain gas, as 50, 50, and 25, respectively; and collision gas,
high. The multiple reaction monitoring (MRM) transitions and the compound settings
were previously optimized and described in [11]. An external standard curve, containing
different concentrations of the peptide (γ-EV diluted in water), was prepared for the absolute quantification of the peptide. The standards were run alongside the samples (γ-EV in
HBSS buffer) in triplicate. The linear range of the standard curve was from 0.016 to 10 µM,
with a linear regression slope R2 of 1 with a CV of <8% for all the dilution points.
2.9. Statistical Analysis
Multiple groups were analyzed using Tukey’s multiple comparison test, following
a one-way analysis of variance (ANOVA) using GraphPad Prism software (version 8.0.2,
San Diego, CA, USA). Before the ANOVA analysis, each data set was analyzed via the
D’Agostino–Pearson test to confirm the normal distribution. Data were presented as
±standard deviation (SD) of the mean, and differences were considered statistically significant with p < 0.05.
3. Results
3.1. Cytotoxicity in Caco-2 Cells
The MTT cell viability assay demonstrated that γ-EV at a concentration of 1 mM
was not toxic to the Caco-2 cells, even after prolonged exposures of 4 and 6 h (Figure 1A).
Similarly, it was found that γ-EV, at concentrations up to 5 mM, was not toxic to the
Caco-2 cells when exposed for 2 h. However, at a 10 mM concentration, the survival rate
dropped to 21% after 2 h (Figure 1B). Therefore, for the variable-dose study, the optimal
concentrations of 2.5 and 5 mM were used.
3.2. Transepithelial Transport of γ-EV across Caco-2 Monolayer Cells
To determine whether the current Papp of 1 mM γ-EV, i.e., 1.56 × 10−6 ± 0.7 × 10−6 cm/s
(reported in our previous study [11]), could be improved or not, a prolonged exposure of
1 mM γ-EV was used for the transepithelial transport across Caco-2 monolayer cells. As
depicted in Figure 2A, the peptide remained stable and intact in the apical layer for up to 6 h
(Figure S1A,B). It was found that the total concentration of the γ-EV peptide significantly
increased in the basolateral region over periods of 4 (p < 0.01) and 6 h (p < 0.001) as
compared to 2 h (Figure 2B); however, the calculated Papp values for each of the time points
showed that 2 h (1.56 × 10−6 ± 0.7 × 10−6 cm/s) had a significantly higher Papp value
(p < 0.01) as compared to 4 h (6.78 × 10−7 ± 0.56 × 10−7 cm/s) and 6 h (7.46 × 10−7 ±
0.8 × 10−7 cm/s) (Figure 2C). This was probably due to the fact that although the peptide
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Figure 2. Time-dependent transport of 1 mM γ-EV across Caco-2 cells. (A) Concentration of γ-EV at different time points
(2, 4, and 6 h) in the apical compartment. (B) Time-dependent increase in the concentration of γ-EV in the basolateral
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did not have a significant change in the rate of transport (Figure 3C). This suggested that
the flux rate was concentration dependent. Furthermore, analysis of the tight-junction
proteins revealed that ZO-1 and claudin expressions were not affected by the increase in
dosage; however, in case of occludin, there was a significant decrease (p < 0.05) in expression for the 5 mM dosage as compared to 1 mM, suggesting that the higher peptide dose
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cytochalasin D also increased the peptide transport by 65% across Caco-2 cells.
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0.4–0.9 nm in the villi and 5–6 nm in the crypts of the intestinal membrane [25]. In our study,
the role of paracellular transport was confirmed with the use of TF30 G, an epithelial barrier
enhancer that enhances the expression of adenosine monophosphate (AMP)-activated
protein kinase mediated ZO-1, claudin-1, and occludin [26]. The transport of γ-EV was significantly decreased in the presence of TF30 G, which described the route to be paracellular
(Figure 5). It has been demonstrated that the paracellular pathway is the most common
route of transport for many bioactive peptides, such as VPP [27], VLPVP [28], RVPSL [18],
HLPLP [20], and GPRGF [21]. In our study, γ-EV also was shown to be transported through
the PepT1 transporter (Figure 6), which is consistent with previous reports suggesting that
most di- and tripeptides are transported through PepT1. Many bioactive peptides, such as
YPI [18], IPP [29], IQW [19], LSW [16], and IRW [22], have been reported to be transported
via both the paracellular and PepT1 routes, while some peptides are transported via both
the paracellular and transcytosis routes. However, so far the existing literature evidence
does not support the transport of a dietary bioactive peptide via both transcytosis and
PepT1, nor any peptide that transports via all three pathways. This is probably related to
the lipid membrane or energy dependence, and further research is required to clarify the
understanding [5].
Earlier studies have shown that at lower peptide concentrations (≤Km ), the transporter
PepT1 is the primary contributor to the total transport rate for the peptides; however, paracellular transport is mostly concentration-dependent. As the concentration increases, the
role of paracellular transport becomes more evident. This is because the PepT1 transporter
becomes saturated at Vmax , and any further increases in the total peptide transport correspond to the passive transport [5]. This could potentially be the reason for the enhanced
rate of transport of γ-EV in the initial 2 h. Furthermore, our study also suggested that the
expression of tight-junction proteins was not altered at concentrations of 1 and 2.5 mM,
but a decrease in occludin expression was observed in the case of 5 mM (Figure S3). The
transport of γ-EV had a Papp in the range of 1.5–2.5 × 10−6 cm/s, depending on the concentration, which was comparable to other bioactive peptides reported in the literature [30].
As previously reported, bioactive peptide transport across the Caco-2 monolayer usually is
in the range of 1.0 × 10−7 to 10 × 10−7 cm/s [5,16,19,24,31,32], and this is similar to any
other bioactive food components, such as flavonoids, catechins, and anthocyanins [33,34].
In addition to Caco-2 being a good experimental model in terms of simulating the human
intestinal membrane, it has its disadvantages as well. One such disadvantage is the lower
expression of uptake transporters as compared to the human intestine, and thus the peptide
permeability through Caco-2 may not be an accurate representation of the actual transport
through the human intestinal membrane [21,24]. Although the permeabilities of bioactive
peptides are generally low (mainly less than 1%) [35], many peptides have still exerted
their bioactivities in vivo, after being absorbed in the bloodstream [36–38].
5. Conclusions
The anti-inflammatory γ-glutamyl dipeptide, γ-EV, was not toxic to the intestinal
epithelial Caco-2 cells up to a concentration of 5 mM, and the peptide could be transported
intact across the epithelial monolayer without becoming degraded by peptidases present on
the apical surface of the intestinal cells. A higher peptide dose of up to 5 mM was found to
be safe and enhanced the permeability of the peptide across the intestinal membrane; however, it was shown to modulate the structural tight-junction protein, so future investigation
is required to decipher the long-term effect of γ-EV on intestinal tight-junction proteins.
Furthermore, the route of transport of γ-EV across the intestinal monolayer was found to
be via the PepT1 and paracellular pathways. Future studies are required to explore the
in vivo bioavailability of γ-EV; however, the current findings highlight the potential of the
application of γ-EV in the formulation of nutraceuticals or functional foods.
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